title: Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins.
abstract: Blood coagulation involves a series of enzymatic protein complexes that assemble on the surface of anionic phospholipid. To investigate whether apolipoproteins affect coagulation reactions, they were included during the preparation of anionic phospholipid vesicles using a detergent solubilization-dialysis method. Apolipoprotein components of high density lipoproteins, especially apolipoprotein A-I, had a pronounced anticoagulant effect. The anionic phospholipids lost their procoagulant effect when the vesicle preparation method was performed in the presence of apolipoprotein A-I. The anionic phospholipid-apolipoprotein A-I particles were 8-10 nm in diameter and contained around 60-80 phospholipid molecules, depending on the phospholipid composition. The phospholipids of these particles were unable to support the activation of prothrombin by factor Xa in the presence of factor Va and unable to support binding of factor Va, whereas binding of prothrombin and factor Xa were efficient. Phospholipid transfer protein was shown to mediate transfer of phospholipids from liposomes to apolipoprotein A-I-containing reconstituted high density lipoprotein. In addition, serum was also shown to neutralize the procoagulant effect of anionic liposomes and to efficiently mediate transfer of phospholipids from liposomes to either apolipoprotein A-I- or apolipoprotein B-containing particles. In conclusion, apolipoprotein A-I was found to neutralize the procoagulant properties of anionic phospholipids by arranging the phospholipids in surface areas that are too small to accommodate the prothrombinase complex. This anionic phospholipid scavenger function may be an important mechanism to control the exposure of such phospholipids to circulating blood and thereby prevent inappropriate stimulation of blood coagulation.
authors.affiliation: Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital, SE-20502 Malmö, Sweden.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Oslakovic
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Krisinger
authors.forename: Astra
authors.initials: A
authors.lastname: Andersson
authors.forename: Matti
authors.initials: M
authors.lastname: Jauhiainen
authors.forename: Christian
authors.initials: C
authors.lastname: Ehnholm
authors.forename: Björn
authors.initials: B
authors.lastname: Dahlbäck
mesh_terms: D000838:Anions / Q000737:chemistry*; D016632:Apolipoprotein A-I / Q000378:metabolism*; D001777:Blood Coagulation / Q000502:physiology*; D001779:Blood Coagulation Factors / Q000378:metabolism*; D005165:Factor V / Q000378:metabolism; D015951:Factor Xa / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008075:Lipoproteins, HDL / Q000378:metabolism; D008081:Liposomes; D010743:Phospholipids / Q000378:metabolism*; D011516:Prothrombin / Q000378:metabolism; D020349:Surface Plasmon Resonance
chemical_list: D000838:Anions; D016632:Apolipoprotein A-I; D001779:Blood Coagulation Factors; D008075:Lipoproteins, HDL; D008081:Liposomes; D010743:Phospholipids; C022475:prothrombinase complex; D005165:Factor V; D011516:Prothrombin; D015951:Factor Xa